Overview of Doloket

Quick Facts

Property	Description
Active Ingredient	Ketorolac tromethamine
Form	Tablets, Sterile Injection Solution, Ophthalmic Solution
Pharmacological Class	Nonsteroidal Anti-inflammatory Drug (NSAID)
Common Use	Short-term management of moderately severe acute pain
Origin	Synthetic compound

What Type of Medicine is Doloket?

Doloket is a potent, prescription-only medicinal entity whose active substance is the synthetic compound Ketorolac tromethamine. It is scientifically classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), belonging to the pyrrolo-pyrrole group of compounds. This drug functions as a non-opioid analgesic, managing pain through peripheral mechanisms rather than by altering central nervous system perception. Pharmacological studies confirm that Ketorolac is a strong agent in this class, clinically recognized for its high analgesic capacity. The drug's identity as an NSAID and a peripherally acting analgesic agent defines its clinical application, distinguishing it from both weaker analgesics and narcotic medications.

Composition and Available Forms of Ketorolac

The composition of Doloket is based on a single-ingredient product, containing only Ketorolac tromethamine alongside necessary pharmaceutical excipients or an appropriate vehicle. This substance is administered in several distinct high-level dosage forms, including conventional oral tablets and a sterile solution for injection for parenteral administration. The drug is also formulated into an ophthalmic solution, allowing for localized topical application to address pain and inflammation in the eye. The availability of both injectable and oral forms supports a flexible approach to patient care.

General Purpose and Benefit of this Potent Analgesic

The general purpose of the drug is the effective short-term management of moderately severe acute pain that requires powerful relief, such as pain experienced after surgical procedures. Its primary mechanism of effect involves functioning as a potent inhibitor of the cyclooxygenase (COX) enzyme system, thereby preventing the production of pain-signaling compounds known as prostaglandins. By limiting the synthesis of these inflammatory mediators, Doloket provides a significant reduction in discomfort and accompanying swelling, positioning it as an effective analgesic agent when high-level pain management is needed.

Regulatory References

Ketorolac: MedlinePlus Drug Information

What side effects are possible with Doloket?

Possible Side Effects and Safety Information

The safety profile of Doloket (Ketorolac tromethamine), a potent Nonsteroidal Anti-inflammatory Drug (NSAID), is characterized by officially documented risks, particularly involving the gastrointestinal, cardiovascular, and renal systems. Adverse reactions are formally classified by frequency in regulatory documents.

Adverse Reaction Scope

Common effects, reported in 1% to 10% of patients, include headache, dizziness, dyspepsia, nausea, and fluid retention (edema). Serious adverse events, classified as rare, are explicitly listed and involve multiple System-Organ Classes (SOCs):

Serious Gastrointestinal Events: Peptic ulceration, bleeding, and perforation of the stomach or intestines. These events may occur without warning.
Serious Cardiovascular Thrombotic Events: The documented risk of myocardial infarction and stroke requires specific safety limitations.
Other Serious Events: Includes acute renal failure and severe dermatological reactions like Stevens-Johnson Syndrome (SJS).

Safety Constraints and Time-Related Patterns

The risk of serious adverse reactions is officially documented to increase with the duration of use. Consequently, the total systemic exposure (all formulations combined) must not exceed 5 days in adults, and the medicine is strictly prohibited for chronic pain management.

Population-specific constraints include a greater documented risk of serious gastrointestinal and renal adverse effects in older adults. The drug is formally contraindicated in patients with advanced renal impairment and during the third trimester of pregnancy, reflecting high regulatory concern for these populations. Concomitant use with other NSAIDs or aspirin is also contraindicated due to cumulative risk.

Overdose and Emergency Response

Overdose Scope

Documented Overdose Presentations: Overdose symptoms following acute ingestion of Doloket, an NSAID, are officially documented to include abdominal pain, nausea, vomiting, epigastric pain, lethargy, and drowsiness. Single overdoses have also been associated with hyperventilation and the development of peptic ulcers or erosive gastritis.

Physiological Systems Affected: The primary systems noted in the official label text are Gastrointestinal, Central Nervous System, and Renal. Severe, rare outcomes include gastrointestinal bleeding, acute renal failure, respiratory depression, and coma.

Emergency-Response Statements: Seek immediate medical attention is required due to the potential for these severe manifestations. Management must be by symptomatic and supportive care following the discontinuation of dosing. There is no specific antidote known for Ketorolac tromethamine overdose.

Overdose Classification (High-Level)

Severity Classification: Manifestations range from generally reversible acute symptoms to severe, potentially life-threatening outcomes such as metabolic acidosis, anaphylactoid reactions, and death (rarely reported in massive NSAID overdoses).

Overdose-Context Constraints: Procedures intended to remove the drug, such as hemodialysis or forced diuresis, are generally considered ineffective due to the high protein-binding nature of the compound. Hospital monitoring may be required based on clinical assessment.

Connection to the Overall Overdose Profile

The regulatory documents define the overdose profile by listing specific clinical presentations and emphasizing the potential for severe systemic complications, particularly affecting the kidneys and the GI tract. This documentation mandates that urgent medical care must be sought immediately. Since no specific antidote is available, the official medical guidance focuses entirely on the provision of timely supportive care.

Therapeutic Uses of Doloket

This medication is generally considered relevant for therapeutic domains where symptoms related to physical discomfort and inflammatory or irritative states may become temporarily overwhelming. The systemic forms are indicated for the short-term management of moderately severe acute pain that is associated with heightened symptoms. It is commonly used when symptoms intensify and supportive relief is needed.

Key Therapeutic Applications

Doloket is applied across domains where additional symptomatic support is needed, primarily addressing intense, acute systemic discomfort in the post-operative setting. Specific applications are relevant across conditions associated with acute episodes, such as managing pain after surgical procedures (including orthopedic and abdominal) and controlling symptoms related to inflammatory or irritative states in the eye. This approach provides support that helps ease the overall symptom burden.

“It is relevant when symptoms create noticeable physiological strain and when additional short-term symptomatic assistance is needed.”

Supportive Relief

This medication is applied in addressing symptoms that interfere with daily comfort during periods of heightened symptoms by assisting with the overall symptom load. The symptomatic relief provided may assist with maintaining functional stability and supports general well-being during symptomatic phases.

High-Level Symptom Support

Domain	Symptom Targeted	Benefit Provided
Systemic	Moderately severe pain, swelling	Supportive relief, easing symptomatic burden
Ocular	Pain, redness, itching	Assists with maintaining functional stability

Regulatory References

FDA DailyMed overview of Ketorolac

Eligibility and Restrictions for Use

Who Can and Cannot Use Doloket?

The eligibility for systemic Doloket (Ketorolac tromethamine) is highly restricted by regulatory authorities based on a patient's medical history and physiological status.

Populations for whom use is Contraindicated

Use is strictly prohibited in patients with a history of peptic ulcer disease or gastrointestinal bleeding, advanced renal impairment, known bleeding disorders (including confirmed cerebrovascular bleeding), and established allergies to aspirin or other NSAIDs. The medicine is also contraindicated for concurrent use with other NSAIDs and during labor, delivery, or lactation. Furthermore, it must not be used for pain relief before surgery (prophylaxis) or in the setting of CABG surgery.

Restricted and Age-Related Eligibility

The medicine is not indicated for use in pediatric patients. For older adults (ge 65 years), patients with moderate renal impairment, or individuals weighing less than 50 kg, use is classified as a special population requiring mandated restricted use to mitigate higher risks.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents define several interaction-related restrictions for Ketorolac. The official profile highlights strict contraindicated combinations due to additive safety risks or significant alterations in drug exposure. Co-administration is formally prohibited with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Aspirin due to the cumulative risk of serious gastrointestinal bleeding and ulceration. The combination with Anticoagulants (such as Warfarin) is contraindicated because Ketorolac inhibits platelet function, which severely increases the risk of haemorrhage.

Exposure and Clearance Interactions

Co-administration with Probenecid is contraindicated because it decreases the clearance and volume of distribution of Ketorolac, leading to clinically increased plasma levels. Similarly, the use of Ketorolac with Lithium salts is prohibited, as Ketorolac decreases Lithium’s renal clearance, which can result in toxic plasma concentrations. Ketorolac may also increase Methotrexate toxicity by decreasing its renal clearance.

Pharmacodynamic Risk and Substance Constraints

The drug may reduce the effectiveness of diuretics and antihypertensive agents (like ACE inhibitors) by inhibiting renal prostaglandin synthesis, which can increase the risk of renal impairment, particularly in volume-depleted patients. The use of any systemic Ketorolac formulation (oral, injectable, nasal) is restricted to a total duration not exceeding 5 days. Use with alcohol is documented to increase the risk of gastrointestinal bleeding.

Mechanism of Action

Doloket's mechanism is defined by direct interference with the body's chemical signaling systems, which results in the alteration of key physiological response pathways.

Inhibiting the Cyclooxygenase (COX) Enzyme System

This drug functions as a non-selective inhibitor by binding to and inhibiting both the COX-1 and COX-2 enzyme isoforms . This initial molecular step halts the enzymatic conversion of Arachidonic Acid into key chemical mediators known as Prostaglandins.

⬇️ Modulation of Prostaglandin-Mediated Nociception

The resulting cessation of Prostaglandin synthesis directly modulates the body’s nociceptive signaling pathway. Prostaglandins, especially PGE2, are crucial for sensitizing peripheral pain receptors (nociceptors) and sustaining central nervous system signaling. By removing this sensitizing agent, the mechanism limits the chemical amplification of nociceptive signaling at the site of tissue irritation and within the spinal cord.

⏱️ Mechanistic Constraint of Non-Selective Action

The inhibition of the constitutive COX-1 isoform is a direct consequence of this mechanism. Because COX-1 is vital for homeostatic processes, such as the regulation of renal blood flow and maintaining the integrity of the gastrointestinal lining, this non-selective action imposes a physiological constraint on homeostatic maintenance.

Dosage and Administration Information

How to Use Doloket

The administration of Doloket is strictly governed by a specific treatment protocol established in official labeling, combining injectable and oral forms for short-term use.

Administration Scope and Rules

Administration Detail	Official Instructions (Adults)
Route of Administration	Intravenous (IV) or Intramuscular (IM) injection, followed by Oral tablets
Total Duration Limit	Combined use of all forms must not exceed 5 days
Oral Use Condition	Tablets are to be used only as continuation therapy following IV or IM administration; they are not for initial treatment
IV/IM Procedural Rule	The IV bolus injection must be administered slowly, over no less than 15 seconds
Timing with Food (Oral)	Oral tablets should be taken with food or an antacid
Missed Dose	Take the missed dose as soon as possible, but skip it if it is near the next scheduled dose. Do not double the dose

Dosing for Specific Patients

Dosage must be reduced for certain patient populations to ensure correct use. This includes patients who are 65 years of age or older, who weigh less than 50 kg, or who have moderately elevated serum creatinine. For these patients, the maximum combined daily dose is often lowered (e.g., to 60 mg/day for IV/IM). The official protocol mandates that patient hypovolemia must be corrected prior to initiating the injectable dose.

Recent Clinical Evidence

Research evidence / Overview of Studies for Doloket

Evidence for Systemic Use in Moderately Severe Acute Pain

The primary research exploring the systemic (oral and injectable) forms of Doloket has been conducted through short-term Randomized Controlled Trials (RCTs). These studies were designed to examine how outcomes related to physical discomfort change over a very short period, typically following surgical procedures like orthopedic or abdominal surgery. Researchers specifically monitored patient-reported outcomes describing perceived discomfort using established measurement scales, and also tracked how the need for other pain relief, such as opioid medications, evolved in the observed populations.

Studies involving adult patients in the post-operative setting examined measurements of pain intensity when comparing patient groups, and reported patterns of differences between those receiving Ketorolac and those receiving a placebo or an active comparison medication. Analyses reported that patients receiving Ketorac demonstrated observed measurements related to opioid consumption that were patterns of difference compared to the placebo groups in the immediate post-operative period. Findings help contextualize how patients reported their experience during periods of heightened symptom activity.

Evidence for Topical Ophthalmic Applications

Research for the topical ophthalmic solution (eye drops) has focused on conditions associated with inflammatory or irritative states in the eye. The main research scenarios involved studies conducted during periods of increased symptom activity following eye surgery, such as cataract extraction or corneal procedures. Studies also explored the use of the topical solution relevant in trials assessing short-term or episodic symptom patterns, specifically when research examined ocular itching linked to seasonal allergies.

These controlled clinical studies reported that patients receiving the eye drop formulation were associated with patterns of difference in ocular pain scores compared to the vehicle following both cataract and refractive surgery procedures. For post-cataract inflammation, trials reported observed changes in inflammatory markers (cell and flare scores) that differed compared to the vehicle group over a two-week period.

What Remains Uncertain in the Study Landscape

Despite the available evidence, the research describes several areas where certainty remains low. First, the limited information for long-term outcomes means that the research only provides insight into short-term changes and does not extend to chronic use. Second, the evidence quality varies across studies, particularly in the comparison of Doloket against different active comparator medications. Finally, certain subgroup findings are uncertain, meaning that research provides context but not individual predictions regarding patients with multiple health issues, as the results apply only to the populations studied in controlled settings.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Doloket (FAQ)

Q: How quickly does Doloket typically start working?

According to the official product information, the analgesic effect often begins within approximately 30 minutes after the injectable dose is administered. The time when the medicine reaches its maximum effect is typically reported as 1 to 2 hours after administration.

Q: What is the longest time someone can take Doloket for?

Regulatory documents clearly define the total treatment duration. The combined use of all systemic forms of the medicine, including both the injectable and the oral tablets, is restricted to a period of no more than 5 days in adults.

Q: Can Doloket make you feel tired or sleepy?

Official product information lists dizziness and headache among the common side effects reported by patients. Because the medicine can affect the central nervous system, drowsiness (somnolence) is also a possible adverse reaction noted in the clinical studies.

Q: What common supplements should I be careful about taking with Doloket?

Regulatory warnings emphasize the importance of disclosing all products being used before starting treatment to a healthcare provider. This disclosure should include all prescription and over-the-counter medicines, as well as herbal products, vitamins, minerals, and other supplements.

Q: Can I take Doloket if I have a history of stomach problems?

Use of this medicine is strictly prohibited (contraindicated) for certain gastrointestinal conditions. This includes patients with a history of peptic ulcer disease, recent gastrointestinal bleeding, or a perforation of the stomach or intestines, as the risk of serious side effects is significantly increased.

Q: How should Doloket be stored, according to official guidance?

Official guidance defines the storage requirements for oral tablets as controlled room temperature (between 15 C and 30 C). The tablets are to be kept in a tight, light-resistant container, and the sterile injection solution must also be protected from light.

Q: Can I take Doloket if I am breastfeeding?

The medicine is contraindicated (prohibited) for use in nursing mothers. This restriction is based on the potential for serious adverse effects in the infant from prostaglandin-inhibiting drugs being present in breast milk.

Q: Does Doloket cause weight gain?

Fluid retention, known as edema, is listed as a common side effect reported in clinical trials (1% to 10% of patients). Official safety information includes a statement that signs of unexplained weight gain should be reported to a healthcare provider.

Q: Is Doloket a controlled substance?

Doloket is scientifically classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Official documents confirm that it is a prescription-only medication and is not classified as a federally controlled substance.

Q: What should I know about Doloket and alcohol consumption?

Regulatory documents clearly describe the interaction between this medicine and alcohol. The use of alcohol while undergoing treatment is documented to increase the risk of serious gastrointestinal bleeding and ulceration.

Q: Does Doloket have a 'ceiling effect' where taking more doesn't help?

Official prescribing information states that increasing the dosage beyond the recommended instructions will not provide better efficacy (pain relief). Taking higher doses is instead documented to significantly increase the risk of serious adverse events.

Q: Is Doloket used for both short-term and chronic conditions?

The medicine is explicitly indicated only for the short-term management of moderately severe acute pain, with a restriction of up to 5 days of total use. It is NOT indicated or approved for the long-term or chronic painful conditions.

Q: What happens if I miss a dose of Doloket?

Official instructions for the oral tablets specify that a missed dose is to be taken as soon as possible, but is to be skipped if it is near the next scheduled dose. The instructions caution against doubling the dose.

Q: Is it normal to feel a mild headache when first starting Doloket?

Official product information lists headache as a common adverse reaction, having been reported in clinical trials by approximately 1% to 10% of patients.

Q: Are there specific food items that must be avoided when taking Doloket?

Official prescribing information states that the oral tablets are to be taken with food or an antacid to help with gastrointestinal tolerance. However, there are no specific food items that are officially required to be avoided in the labeling.

Q: What is the typical duration of effect for a single dose of Doloket?

The typical duration of the analgesic effect for a single dose is usually described in official documents as lasting 4 to 6 hours.

Q: Does Doloket affect driving or operating machinery?

Adverse effects such as dizziness, drowsiness, and somnolence (sleepiness) have been reported. These effects may potentially impair the ability to safely drive or operate complex machinery.

Q: What is the official classification of Doloket in terms of drug schedules?

Doloket is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and is not listed as a drug scheduled under the US Controlled Substances Act.

Q: Can Doloket be taken by people with diabetes?

The official labeling does not list diabetes as a specific contraindication for use. However, the medicine carries documented risks of renal (kidney) impairment, which may be heightened in patients with pre-existing conditions.

Q: How do researchers measure the success of Doloket in clinical trials?

Studies commonly measured success by monitoring patient-reported outcomes that describe the perceived level of discomfort or pain intensity. Researchers also tracked changes in the need for other pain relief medications, such as opioid medications.

Q: Is there a generic version of Doloket available?

The active ingredient in this medicine is ketorolac tromethamine. This substance is available as a generic medication.

Q: What are the main risks associated with long-term use of Doloket?

The risk of serious adverse events, including gastrointestinal bleeding/ulceration and cardiovascular thrombotic events (like heart attack or stroke), is formally documented to increase with the duration of use. This is why the medicine is prohibited for chronic use.

Q: Are there any common interactions with common heartburn medications?

Official guidance states that oral tablets may be taken with an antacid. However, the medicine is contraindicated (prohibited) for anyone with a history of peptic ulcer disease, regardless of concurrent use of other heartburn medications.

Q: Why is it advised to avoid Doloket during the last trimester of pregnancy?

Official warnings indicate that use in the third trimester of pregnancy is restricted. This is due to the risks it poses to the fetus, which may include premature closure of the ductus arteriosus and the potential to inhibit uterine contractions during labor and delivery.

Q: Does taking Doloket affect the results of any lab tests?

Official product information notes that the medicine can inhibit platelet aggregation, which may result in a prolongation of bleeding time. It has also been documented to cause elevations of liver enzymes in some patients.

Q: What is the standard guidance if Doloket causes stomach upset?

The official protocol for oral tablets specifies that they are to be taken with food or an antacid. This guidance is designed to help mitigate the risk of gastrointestinal irritation and common issues like dyspepsia (stomach upset).

Q: Does Doloket have a black box warning from the FDA?

Yes, the drug is subject to multiple warnings within a Boxed Warning (often called a 'black box warning') in its official labeling. These warnings concern the risk of serious gastrointestinal, cardiovascular, and bleeding-related adverse events.

Q: Is the safety profile of Doloket well-established?

The safety profile, including extensive warnings and contraindications, is officially documented and formally classified in regulatory guidelines. This includes specific limitations concerning the gastrointestinal, cardiovascular, and renal systems, and the presence of a Boxed Warning.

Q: Are there any specific lifestyle changes recommended while on Doloket?

Official documents contain few specific lifestyle recommendations beyond general safety cautions. The only specific constraint mentioned in the interactions section is the need to avoid or strictly limit alcohol consumption due to the increased risk of gastrointestinal bleeding.

Q: What is the mechanism of action of Doloket, in simple terms?

The medicine works by acting as an inhibitor that blocks specific enzymes (known as COX-1 and COX-2) in the body. This process stops the body from making prostaglandins, which are chemical mediators that cause pain and inflammation.

How should Doloket be stored and disposed of?

How to Store and Dispose of Doloket?

Regulatory agencies define specific storage and disposal requirements for Doloket (Ketorolac tromethamine) to ensure product stability and safety. These requirements vary by formulation:

1. Official Storage Conditions

Dosage Form	Required Temperature	Handling and Protection
Oral Tablets	Controlled Room Temperature (15 C to 30 C)	Store in a tight, light-resistant container; keep away from excessive moisture.
Injection Solution	Room Temperature (20 C to 25 C)	Protect from light; must remain in the original carton until use; do not use if particulate matter is present.
Ophthalmic Solution	Room Temperature (20 C to 25 C)	Keep from freezing; keep the container tightly closed.

2. Stability and Disposal Rules

Stability: Single-use injection vials are to be discarded immediately after use. The ophthalmic solution must be disposed of one month after opening.
Child Safety: All forms must be stored out of the sight and reach of children.
Disposal: Unused or expired medication must be disposed of in accordance with all local and national regulations. To protect the environment, the product must not be thrown into wastewater.

Doloket